| Term | Count | Pvalue | |||
| Neuroactive ligand-receptor interaction | 22 | 9.07775E−22 | |||
| AGE-RAGE signaling pathway in diabetic complications | 14 | 2.82127E−17 | |||
| Fluid shear stress and atherosclerosis | 14 | 1.6426E−15 | |||
| Non-alcoholic fatty liver disease | 14 | 1.90333E−14 | |||
| cAMP signaling pathway | 15 | 5.65367E−14 | |||
| cGMP-PKG signaling pathway | 13 | 2.78556E−13 | |||
| Inflammatory bowel disease | 9 | 9.4159E−12 | |||
| Adipocytokine signaling pathway | 9 | 1.64559E−11 | |||
| Calcium signaling pathway | 12 | 2.26665E−11 | |||
| IL-17 signaling pathway | 9 | 2.56325E−10 | |||
| HIF-1 signaling pathway | 9 | 2.34888E−09 | |||
| TNF signaling pathway | 8 | 2.21697E−08 | |||
| AMPK signaling pathway | 8 | 5.07055E−08 | |||
| inflammatory mediator regulation of trp channels | 7 | 3.35772E−07 | |||
| Toll-like receptor signaling pathway | 7 | 3.35772E−07 | |||
| NOD-like receptor signaling pathway | 7 | 8.99714E−06 | |||
| Drug metabolism-cytochrome P450 | 5 | 1.28935E−05 | |||
| Glycine, serine and threonine metabolism | 4 | 2.60439E−05 | |||
| Adrenergic signaling in cardiomyocytes | 6 | 3.76567E−05 | |||
| NF-kappa B signaling pathway | 5 | 5.66793E−05 | |||